Furthermore, imatinib inhibits the expression of the glucose transporter Glut1 in BCR-ABL-positive, but not in BCR-ABL-negative, chronic myeloid leukemia cells [40]. Here, SLC2A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.